Trials / Completed
CompletedNCT06161259
Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment
A Phase I Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Leritrelvir(RAY1216)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of Leritrelvir(RAY1216)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Leritrelvir(Ray1216) | Participants receive Leritrelvir orally. |
Timeline
- Start date
- 2023-09-14
- Primary completion
- 2023-10-01
- Completion
- 2023-10-07
- First posted
- 2023-12-07
- Last updated
- 2023-12-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06161259. Inclusion in this directory is not an endorsement.